ASTARIA

Astaria Global has been advancing its proprietary line of α2M plasma technologies to introduce Alpha2EQ for inflammation/degeneration of joints in horses. Alpha2EQ is powered by the advanced, patented AlphaActive Concentrate Process. AlphaActive is a highly improved process leveraging PRP methodology derivative of Platelet Poor Plasma (PPP) that concentrates plasma proteins from the equine patient’s own blood. This process isolates the α2M molecule, which is a powerful inhibitor of cartilage catabolic factors and slows the progression of osteoarthritis by preventing cartilage breakdown and loss. The patented, proprietary filtration process removes the harmful proteins that can remain in other autologous plasma products to allow for a pure α2M product with no inflammatory cytokines. It is the only autologous process to concentrate α2M for mammals to obtain a U.S. patent. 

Alpha2EQ is a unique treatment of cartilage-based pathology and inflammatory arthritis. A proprietary kit has been developed and FDA approved in the human market. α2M can not only inhibit the associated inflammatory cascade but also disrupt the catabolic process of cartilage degeneration. α2M is a major plasma glycoprotein best known for its ability to inhibit a broad spectrum of serine, threonine and metalloproteases by a unique bait and trap method.